

- Heterozygotes may develop venous thrombosis and thromboembolism (rare prior to age 20 y). Protein C levels are 35–65% of normal.
- Acquired causes: Hepatic dysfunction, vitamin K deficiency, DIC
- Long-term anticoagulation with warfarin in pts with Hx of thrombosis. (Heparin therapy should be continued until warfarin is at therapeutic levels to prevent skin necrosis.)
- Acute thrombosis may require transfusions of FFP to increase protein C levels.
- During pregnancy, treat with LMWH during and for 4–6 wk after delivery.
- Homozygotes: Periodic FFP or purified protein C concentrate transfusions to provide protein C.
- Acquired:
  - Vitamin K deficiency: Parenteral vitamin K
  - DIC: Treatment of underlying cause

### Usual Treatment

- Heterozygotes:
  - If acute thrombosis, start heparinization (heparin or high-dose LMWH).

### Assessment Points

System	Effect	Assessment by Hx	PE	Test
HEENT	Retinal vein thrombosis	Hx of vision problems	Ophthalmoscopic exam	
CV	MI Angina Peripheral arterial disease	Hx of MI, angina Peripheral vascular thrombosis	Peripheral pulses	ECG
RESP	Pulm embolism	Hx of previous pulm embolism		
GI	Mesenteric thrombosis	Hx of bowel infarction		
HEME	Thrombophlebitis	Hx (and family Hx) of thrombophlebitis, pulm embolism	Exam of veins in legs, evidence for lower extremity postthrombotic syndrome	Screen for hypercoagulable state: PTT, proteins C and S, factor V Leiden, anti-phospholipid antibody, antithrombin 3
RENAL	Renal vein and artery thrombosis	Hx of renal problem		BUN/Cr Urine protein
DERM	Necrosis	Cutaneous necrosis after warfarin is begun	Cutaneous necrosis	
CNS	Intracerebral artery thrombosis	Hx of CVA, TIA	Neurologic exam	

**Key References:** Goldenberg NA, Manco-Johnson MJ: Protein C deficiency, *Haemophilia* 14(6):1214–1221, 2008; Lipe B, Ornstein DL: Deficiencies of natural anticoagulants, protein C, protein S and anti-thrombin, *Circulation* 124(14):c365–c368, 2011.

### Perioperative Implications

#### Preoperative Preparation

- For homozygotes and symptomatic heterozygotes, FFP and protein C concentrates can be administered to increase protein C levels.
- Warfarin can be stopped a few days before surgery to allow PT to return to normal range and heparin administered until surgery.
- Intermittent pneumatic compression stocking can be placed prior to induction of anesthesia.

#### Airway

- Some have suggested that the ETT cuff not be inflated to prevent tracheal venous thrombosis.
- In neonates, there should be an audible leak.

#### Preinduction/Induction

- RA preferable if possible

#### Maintenance

- Special attention can be paid to positioning to reduce venous and arterial stasis.
- Maintain adequate hydration to reduce thrombosis risk.
- Have propensity to thrombose central venous cath, so minimize use. If cath required, continually ensure patency.
- FFP and/or protein C concentrates should be given to pts with prior thrombotic manifestations and for prolonged operations.

#### Adjuvants

- Intermittent pneumatic compression stockings can be used.
- Postop heparinization should be started as soon as deemed safe.

### Anticipated Problems/Concerns

- Increased risk of thrombosis, especially thrombophlebitis and pulm embolism
- When switching from heparin anticoagulation to warfarin, heparin should be continued until warfarin has achieved therapeutic effect to decrease risk of skin necrosis.

## Pulmonary Atresia

Nirvik Pal | Mark T. Nelson

### Risk

- PA/IVS occurs in 3% of all CHD and has a prevalence of 0.07:1000 live births.
- PA/VSD occurs in 3.4% of all CHD.
- 20% of all cases of TOF are physiologically similar to PA/VSD due to extreme pulm artery stenosis.
- Males are affected more than females.

### Perioperative Risks

- RV failure (due to volume overload, pressure overload or both)
- Hypoxemia (leading to metabolic acidosis)
- Myocardial ischemia secondary to aberrant coronary circulation

### Worry About

- RV-dependent coronary circulation in PA/IVS (rapid boluses of fluid through central line may precipitate myocardial ischemia).

- Maintain a patent ductus arteriosus (continue prostaglandin infusion).
- “Suicide RV” is sudden release of pulm valve obstruction leading to hyperdynamic RV and subpulmonic obstruction of RV outlet. Treatment involves a β blockade.
- Hyperventilation and hyperoxia when excess “pulmonary-steal,” leading to low cardiac output syndrome and necrotizing colitis (maintain oxygen saturation to 70–80%), mainly in PA/VSD.

### Overview

- Physiologically, PA/IVS and PA/VSD present as two extremes of the same spectrum. Usually associated with other cardiac lesions (e.g., patent foramen ovale, patent ductus arteriosus, possible VSD, ASD).
- PA/IVS often presents with varying extent of RV maldevelopment, TV hypoplasia and stenosis, and RV-dependent coronary blood flow (due to

abnormal coronary arteries arising from sinusoids in the RV outlet musculature).

- PA/VSD, on the other hand, the RV by virtue of ‘flow-growth phenomenon due to the presence of VSD, enjoys more blood flow and as a result is more completely developed. However, due to the reduced pulm blood flow in PA/VSD, MAPCA develop compensating for the limited blood flow in the mal-developed PA.

### Etiology

- Congenital

### Usual Treatment

- Prostaglandin E<sub>1</sub> infusion
- Surgical correction
- Infective endocarditis prophylaxis
- Palliative therapy

**Surgical Treatment**

- With PA/VSD (usually RV well developed), goal is “two-ventricle repair”:
  - Implement a staged repair with BTS early on, followed by VSD closure and valved RV-PA conduit (Rastelli procedure).
  - If multiple MAPCAs present, then implement “unifocalization” (surgically creating a neopulmonary artery by fusing all MAPCAs), followed by VSD closure and valved conduit from RV to neo-PA (Rastelli procedure).
- With PA/IVS (often RV maldeveloped and coronary artery obstruction), goal is “two-ventricle repair,” if possible, or else “single-ventricle repair” and eventual heart transplantation. Monitor size/development of RV and extent of coronary artery malformation/obstruction:
  - For adequate RV size for future growth and no coronary malformation, transannual RV outflow

patch or radiofrequency assisted valvotomy and dilatation and a systemic-to-PA shunt for future “two-ventricle repair.”

- For small RV (monopartite) and/or coronary malformation, RV outflow patch or dilatation not recommended so as to maintain high RV pressure necessary for coronary blood flow. Stage surgery with BTS, Glenn shunt, total cavo-pulmonary connection (single-ventricle repair), and/or heart transplant.

**Assessment Points**

System	Effect	Assessment by Hx	PE	Test
CV	RV failure Hypoxemia/metabolic acidosis	SOB	Cyanosis	ECG: RA enlargement, ECG-QRS axis 30–90° CXR: Decreased pulm vascular markings ABG ECHO: PV annulus size, flow across PV, TV size and function, RVOT obstruction, ductus arteriosus, PA anatomy Cardiac cath: Confirm ECHO findings and detect state of coronary blood flow, MAPCAs
RESP	Decreased pulm blood flow	SOB	Tachypnea	ECHO, cardiac cath
SYSTEMIC	Signs of RV failure	Hepatomegaly		

**Key References:** Malhotra SP, Hanley FL: Surgical management of pulmonary atresia with ventricular septal defect and major aortopulmonary collaterals: a protocol-based approach, *Semin Thorac Cardiovasc Surg Card Surg Annu* 12:145–151, 2009; Mi YP, Chau AK, Chiu CS, et al.: Evolution of the management approach for pulmonary atresia with intact ventricular septum, *Heart* 91(5):657–663, 2005.

**Perioperative Implications****Preoperative Preparation**

- Ascertain physiologically predominant PA/IVS versus pulm valve stenosis or PA/VSD versus TOF.
- Cath suite intervention versus surgical intervention.
- Patency of ductus arteriosus.
- Maintain pulm blood flow.
- Avoid hyperoxia and hyperventilation in PS/VSD.
- RV dysfunction.
- Presence of RV-dependent coronary circulation.
- Type of shunt to be performed.
- Which systemic artery is to be used for shunt? Avoid during CVP attempts.
- Degree of hypoxemia, metabolic acidosis.

**Monitoring**

- Standard ASA monitors.
- A-line:
  - Use umbilical artery if good trace.
  - For radial artery, use opposite side of shunt.
  - Use partial clamping of subclavian artery for BTS, with the same implication for pulse oximeter placement and preductal and postductal pulse oximeter.

- CVP for resuscitation drugs.
- Temp/warmers.
- Bubble precaution.

**Airway**

- ET

**Preinduction/Induction**

- Continue prostaglandin infusion (0.03–0.1 µg/kg per min) in ductal dependent pts.
- Inhalational induction may be chosen to relax RV infundibulum versus IV ketamine to maintain vascular resistance, depending on presenting predominant physiology and physician preference.
- ET/CO<sub>2</sub> may significantly underestimate PaCO<sub>2</sub> due to limited pulm blood flow.
- Goals: Decrease PVR (to help maintain pulm blood flow), and maintain normal SVR (to avoid desaturation and hypoxemia due to shunt reversal of L-to-R shunt across the VSD by drop in SVR) in PA/VSD.
- Avoid increases in pulm vascular resistance (coughing, bucking; increased PEEP; increased CO<sub>2</sub>; decreased PO<sub>2</sub>).

- Avoid extreme hyperoxia/hypocarbica in PA/VSD, as this may result in increased L-to-R shunting and systemic hypotension.

**Maintenance**

- Normothermia
- Normal filling volumes
- Normal myocardial contractility
- Aiming for early extubation

**Extubation**

- As early as reasonably safe

**Postoperative Period**

- Pediatric cardiac ICU.
- Continue prostaglandin infusion after palliative repair.

**Anticipated Problems/Concerns**

- Palliative surgery only
- Definitive procedure later (e.g., Fontan, Rastelli)
- Progressive hypoxemia: Inadequate BT shunt flow or ductus closure

**Pulmonary Embolism**

Ronald G. Pearl

**Risk**

- Incidence of pulmonary embolism in USA: 600,000/y
- No racial predilection
- Risk factors same as those for DVT

**Perioperative Risks**

- Presents a risk for hypoxemia and right heart failure.
- Periop mortality of 50–90% for acute thromboendarterectomy and of ~10% for chronic thromboendarterectomy.
- Postop pulm embolism in up to 1% of surgical pts.
- Pulm embolism accounts for 20–30% of deaths associated with pregnancy.

**Worry About**

- Recurrent pulm embolism (30% mortality if not treated)
- Right heart failure and CV collapse
- Hypoxemia
- Hemorrhage in pts on anticoagulants or thrombolytics

**Overview**

- Pulm embolism found in ~20% of autopsied pts.
- Clinical presentation may range from asymptomatic to chest pain and hypoxemia to CV collapse depending on magnitude of the embolus.
- Signs (tachycardia, tachypnea, calf swelling) and symptoms (dyspnea, pleuritic chest pain, calf pain) have low sensitivity and specificity.

- Most pts have DVT (and surgical pts may have pelvic vein thrombi).
- Dx should be based on positive CT pulm angiography after use of a validated clinical decision rule; pulm angiogram should no longer be used.
- Negative D-dimer test excludes Dx in selected low probability pts.

**Etiology**

- Acquired disease.
- Risk factors present in almost all pts include age >40 y, obesity, malignancy, recent surgery, trauma, pregnancy, immobilization, estrogen use, prior Hx of DVT, and hypercoagulable state (factor V Leiden, deficiency of protein C, protein S, or antithrombin III).